Showing 1 - 11 results of 11 for search 'Michael J. Sorich', query time: 0.04s Refine Results
  1. 1
    Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing

    Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing by Warit Ruanglertboon, Michael J. Sorich, Ashley M. Hopkins, Andrew Rowland

    Published 2021-04-01
    Get full text
    Article
  2. 2
    Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab

    Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab by Andrew Rowland, Ashley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, Michael J Sorich

    Published 2020-05-01
    Get full text
    Article
  3. 3
    Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials

    Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised C... by Arkady T Manning-Bennett, Julie Cervesi, Pierre-Alain Bandinelli, Michael J Sorich, Ashley M Hopkins

    Published 2023-02-01
    Get full text
    Article
  4. 4
    Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease

    Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease by Lauren A. Newman, Zivile Useckaite, Jillian Johnson, Michael J. Sorich, Ashley M. Hopkins, Andrew Rowland

    Published 2022-01-01
    Get full text
    Article
  5. 5
    Importance of between and within Subject Variability in Extracellular Vesicle Abundance and Cargo when Performing Biomarker Analyses

    Importance of between and within Subject Variability in Extracellular Vesicle Abundance and Cargo when Performing Biomarker Analyses by Lauren A. Newman, Alia Fahmy, Michael J. Sorich, Oliver G. Best, Andrew Rowland, Zivile Useckaite

    Published 2021-02-01
    Get full text
    Article
  6. 6
    A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

    A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials by Lee X. Li, Mark A. Socinski, Ganessan Kichenadasse, Christos S. Karapetis, Adel Shahnam, Ross A. McKinnon, Andrew Rowland, Ashley M. Hopkins, Michael J. Sorich

    Published 2024-03-01
    Get full text
    Article
  7. 7
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data

    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data by Natansh D. Modi, Jin Quan Eugene Tan, Andrew Rowland, Bogda Koczwara, Ahmad Y. Abuhelwa, Ganessan Kichenadasse, Ross A. McKinnon, Michael D. Wiese, Michael J. Sorich, Ashley M. Hopkins

    Published 2021-03-01
    Get full text
    Article
  8. 8
    The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data

    The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data by Natansh D. Modi, Jin Quan Eugene Tan, Andrew Rowland, Bogda Koczwara, Bogda Koczwara, Ganessan Kichenadasse, Ganessan Kichenadasse, Ross A. McKinnon, Michael D. Wiese, Michael J. Sorich, Ashley M. Hopkins

    Published 2020-07-01
    Get full text
    Article
  9. 9
    Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials

    Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials by Sara A. Almansour, Mohammad A. Y. Alqudah, Ziad Abuhelwa, Humaid O. Al-Shamsi, Mohammad H. Semreen, Yasser Bustanji, Nelson C. Soare, Ross A. McKinnon, Michael J. Sorich, Ashley M. Hopkins, Ahmad Y. Abuhelwa

    Published 2024-01-01
    Get full text
    Article
  10. 10
    Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials

    Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials by Sara A. Almansour, Mohammad A. Y. Alqudah, Ziad Abuhelwa, Humaid O. Al-Shamsi, Ahmad Alhuraiji, Mohammad H. Semreen, Yasser Bustanji, Karem H. Alzoubi, Natansh D. Modi, Ross A. Mckinnon, Michael J. Sorich, Ashley M. Hopkins, Ahmad Y. Abuhelwa

    Published 2024-08-01
    Get full text
    Article
  11. 11
    A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies

    A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies by Natansh D. Modi, Ganessan Kichenadasse, Tammy C. Hoffmann, Mark Haseloff, Jessica M. Logan, Areti A. Veroniki, Rebecca L. Venchiarutti, Amelia K. Smit, Haitham Tuffaha, Harindra Jayasekara, Arkady Manning-Bennet, Erin Morton, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins

    Published 2023-10-01
    Get full text
    Article

Search Tools: